Natalizumab

ANTI-MAL2 CLONE 1K18 ZOOMAB« RABBIT MONOCLONAL

ANTI-MAL2 CLONE 1K18 ZOOMAB« RABBIT MONOCLONAL

Immunogen Synthetic peptide directed towards the N terminal region of human MAT2B Sequence Synthetic peptide located within the following region: KEFQQNNWHAVGCGFRRARPKFEQVNLLDSNAVHHIIHDFQPHVIVHCAA Physical form Purified antibody supplied in

ANTI-MICU1 CLONE 1H13 ZOOMAB« RABBIT MONOCLONAL

ANTI-MICU1 CLONE 1H13 ZOOMAB« RABBIT MONOCLONAL

Anti-MMS22L MMS22-like, DNA repair protein, 25ul UN 1687 6.1

Immunogen Synthetic 16 amino acid peptide from C-terminal cytoplasmic domain of human MRGPRX2 / MRGX2. Percent identity with other species by BLAST analysis: Human, Chimpanzee, Gorilla (100%): Orangutan (94%): Gibbon, Monkey (88%).

ANTI-MXRA8 CLONE 1F4 ZOOMAB« RABBIT MONOCLONAL

ANTI-MXRA8 CLONE 1F4 ZOOMAB« RABBIT MONOCLONAL

Physical form Supplied in PBS with 0.09% (W/V) sodium azide Disclaimer Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for

Anti-NK1.1 is useful for Immunohistochemistry, Immunoprecipitation, and Flow Cytometry using mouse spleen cells, or an appropriate cell type (where indicated). Researchers should determine optimal titers for applications that are not stated.

Obinutuzumab is a humanized anti-CD20 monoclonal antibody, originated by GlycArt Biotechnology AG and developed by Roche as a cancer trea&tradeent. It was approved under the trade name Gazyva by the US FDA in 2013, and as Gazyvaro by the EMA in